openPR Logo
Press release

Oncobiologics expound on biosimilar CMC in New Jersey this November

08-17-2017 11:25 AM CET | Health & Medicine

Press release from: SMi Group

Oncobiologics expound on biosimilar CMC in New Jersey this

Oncobiologics, developers and manufacturers of complex biosimilar therapeutics, will be presenting two exclusive sessions at SMi Group’s 4th annual Biosimilars North America conference in New Jersey this November.

Principal Scientist Hiten Gutka will discuss considerations for drug product and formulation development. The presentation will focus on excipient quality and influence on biosimilar drug product quality and stability, as well as container closure effect on stability of the biosimilar.

Rajani Srikakulam, also a Principal Scientist, will present a session on functional similarity assessment which talks about the importance of functional assays/bioassays in biosimilar development and why they are as important as in-depth structural characterization. The talk will also discuss how to select appropriate bioassay methodologies as well as tiering of functional attributes based on mechanism of action and known clinical relevance.

Hiten and Rajani join a speaker line-up comprised of experts shaping up the biosimilars landscape in North America including representatives from Sandoz, Harvest Moon Pharmaceuticals, Momenta, FUJIFILM Diosynth, Pfenex, Adelio, Covance, Zuckerman & Spaeder and more.

The full roster of speakers and their topics can be found on

SMi’s Biosimilars North America conference will explore significant developmental topics within the sector including the impact of FDA’s newly implemented biosimilar interchangeability guidelines, the US market access landscape, and biosimilars of orphan drugs.

Registration is now live on the event website and there For more information visit

4th Biosimilars North America
November 15 & 16, 2017
Renaissance Woodbridge Hotel, Iselin, NJ, USA

--- END ---
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

1 Westminster Bridge Road, London, SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oncobiologics expound on biosimilar CMC in New Jersey this November here

News-ID: 672015 • Views: 476

More Releases from SMi Group

Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK. The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines. Darren Green, Director of Computational Chemistry at GSK will be chairing at
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety. SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA. The 2022 Conference theme is
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022. SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022. Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022. This event will convene on February 9th – 10th 2022,

All 5 Releases

More Releases for Oncobiologics

Adalimumab Biosimilar Market 2019-2025: Industry Business Trends, Segments and K …
The Asia-Pacific Adalimumab Biosimilar Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. The tumor necrosis factor inhibitor Humira (adalimumab, AbbVie) is an established biologic treatment for a number of immune-mediated inflammatory diseases, including rheumatoid arthritis (RA), psoriatic arthritis and inflammatory bowel disease. The lower cost of biosimilars compared to patented biologics and positive outcomes in clinical trials
New Study On Systemic Idiopathic Juvenile Arthritis Treatment Market 2019-2025| …
UpMarketResearch offers a latest published report on “Global Systemic Idiopathic Juvenile Arthritis Treatment Market Industry Analysis and Forecast 2019-2025” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 111 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. The report contains basic, secondary and advanced information pertaining to the Systemic Idiopathic
Attendee list for Biosimilars North America 2017 released
SMi Group has released a preliminary attendee list for its 4th annual Biosimilars North America Conference, taking place on November 15 and 16, 2017 in Iselin, New Jersey. With the event taking place in three weeks, confirmed attendees include delegations from over thirty biotech and big pharma companies shaping up the biosimilars landscape including Alexion, AmerisourceBergen, Covance, Janssen, Lupin Pharmaceuticals, MedImmune, Momenta, Oncobiologics, Pfizer, Sandoz, Teva and more. Also in
Global Adalimumab Biosimilar Market 2017 : Oncobiologics, Pfizer, Samsung Bioeps …
QY Market Research published, Top Manufacturers Analysis Of Bidets Research Report. A market study based on the "Adalimumab Biosimilar Market" across the globe, recently added to the repository of Market Research, is titled ‘Global Adalimumab Biosimilar Market 2017’. The research report analyses the historical as well as present performance of the worldwide Adalimumab Biosimilar industry, and makes predictions on the future status of Adalimumab Biosimilar market on the basis of
Pfenex CEO explores the future of biosimilars in North America
SMi Group has announced that Mr Patrick Lucy, CEO of Pfenex, has joined the speaker line-up for the 4th annual Biosimilars North America conference which takes place on November 15 & 16 in New Jersey. Patrick will present a special keynote address giving an overview of the biosimilars market, including the key milsestones and hurdles the industry has overcome. He will also share some top tips on what to keep
Mylan explores the patient-centric road to biosimilars
SMi Group has announced that Mr Chrys Kokino, Head Biologics Commercial at Mylan has joined the speaker line-up for the 4th annual Biosimilars North America conference in New Jersey. Chrys will present a talk entitled "The Road to Biosimilars: Reaching our destination with the patient in mind". This session, focusing on biosimilar usability and effectivity, will look into strategies, obstacles and lessons learned from the global market and adapting these